Emergent BioSolutions Files Routine 8-K on Jan 9 Event

TL;DR

**EBS filed a routine 8-K, nothing major to see here.**

AI Summary

Emergent BioSolutions Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 9, 2024. This filing is a routine disclosure under 'Other Events' and 'Financial Statements and Exhibits,' indicating no major new financial or operational news. For investors, this means there's no immediate significant positive or negative catalyst from this specific filing, suggesting a neutral impact on the stock price based solely on this report.

Why It Matters

This filing is a standard disclosure, indicating no immediate material changes to Emergent BioSolutions' financial health or operations that would significantly impact investors.

Risk Assessment

Risk Level: low — This 8-K is a standard, non-event-specific filing, posing minimal direct risk to investors.

Analyst Insight

Given this is a routine 8-K with no specific material event disclosed, a smart investor would not make any immediate trading decisions based solely on this filing. It's important to monitor future filings for more substantive news.

Key Players & Entities

• Emergent BioSolutions Inc. (company) — the registrant filing the 8-K
• January 9, 2024 (date) — date of the earliest event reported
• January 11, 2024 (date) — date the 8-K was filed
• 001-33137 (other) — Commission File Number for Emergent BioSolutions Inc.
• EBS (other) — Trading Symbol for Emergent BioSolutions Inc. Common Stock

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, Par Value $0.001 per share EBS New York Stock Exchange
• $235.8 million — EO-CBRND), for a maximum value of up to $235.8 million to supply the Company's product BioThra
• $20.1 million — ere is a guaranteed purchase minimum of $20.1 million by the U.S. Department of Defense, with
• $20 million — future orders estimated to be at least $20 million for each following year for a total awa

Filing Documents

• ebs-20240109.htm (8-K) — 29KB
• pressrelease_011024ebsbiot.htm (EX-99.1) — 11KB
• imagea.jpg (GRAPHIC) — 7KB
• 0001367644-24-000004.txt ( ) — 181KB
• ebs-20240109.xsd (EX-101.SCH) — 2KB
• ebs-20240109_lab.xml (EX-101.LAB) — 25KB
• ebs-20240109_pre.xml (EX-101.PRE) — 13KB
• ebs-20240109_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 9, 2024, Emergent BioSolutions Inc. (the "Company") entered into an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract (the "Procurement Contract") with the U.S. Department of Defense and led by The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), for a maximum value of up to $235.8 million to supply the Company's product BioThrax (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The Procurement Contract is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that could extend the Procurement Contract to September 30, 2033. Under the initial five-year of the Procurement Contract, there is a guaranteed purchase minimum of $20.1 million by the U.S. Department of Defense, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on January 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: January 11, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR